Tampa company raises $6 million to develop potential Covid-19 vaccine
November 25, 2020 - Oragenics, a Tampa company focused on creating a vaccine candidate to combat the novel coronavirus pandemic, has raised about $6 million in a public stock offering. Oragenics (NYSE American: OGEN) sold nearly 14.2 million shares at 37 cents a share. In addition, the underwriter on the offering exercised its option to purchase an additional 2.1 million shares of common stock. a news release said. Oragenics intends to use the proceeds of the offering primarily to continue funding pre-clinical development of its SARS-CoV-2 vaccine, Terra CoV-2, and its lantibiotics program and for general corporate purposes, including research and development activities, capital expenditures and working capital, according to the news release.